Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash
I'm LongbridgeAI, I can summarize articles.Fate Therapeutics updated its corporate presentation, highlighting FT819 Phase 1 safety and efficacy, with RECLAIM-LN Phase 2 enrollment planned for late 2026. FT836 is enrolling in a pan-solid tumor Phase 1 trial showing preliminary activity. Financially, the company reported $174.8M in cash and investments as of Q1 2026, with a runway into 2028 and a 20% year-over-year reduction in operating expenses.
Fate Therapeutics updated its corporate presentation highlighting FT819 clinical progress, FT836 enrollment and a Q1 2026 cash balance of $174.8M.
Key Highlights:
- Updated corporate presentation released for EULAR 2026, attached as Exhibit 99.1 to the 8-K.
- FT819 Phase 1 shows favorable safety (no DLTs, no grade ≥3 CRS/ICANS/GvHD) and rapid, sustained clinical improvements.
- RECLAIM-LN Phase 2 (900M single dose, bendamustine conditioning) planned to start 2H 2026; enrollment N=53, BLA targeted in 2028.
- FT836 pan–solid tumor Phase 1 now enrolling with preliminary anti-tumor activity and tumor trafficking without conditioning chemo.
- Q1 2026 financial snapshot: $174.8M cash and investments, runway into 2028, and a 20% YoY OpEx reduction with $8.6M total quarterly savings vs Q1 2025.
Original SEC Filing: FATE THERAPEUTICS INC [ FATE ] - 8-K - Jun. 04, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.